The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
2011; Elsevier BV; Volume: 22; Linguagem: Inglês
10.1093/annonc/mdr284
ISSN1569-8041
AutoresEric Van Cutsem, Mario Dicato, Ravit Geva, Nadir Arber, Yu Jeong Bang, Al B. Benson, Andrés Cervantes, Eduardo Díaz‐Rubio, Michel Ducreux, R. Glynne‐Jones, Axel Grothey, Daniel G. Haller, Karin Haustermans, Dale Kerr, Bernard Nordlinger, John L. Marshall, B. Minsky, Yoon‐Koo Kang, Roberto Labianca, Florian Lordick, Atsushi Ohtsu, N. Pavlidis, A. Roth, Philippe Rougier, Hans‐Joachim Schmoll, Alberto Sobrero, Josep Tabernero, Cornelis J.�H. van de Velde, John Zalcberg,
Tópico(s)Esophageal Cancer Research and Treatment
ResumoWell-recognized experts in the field of gastric cancer discussed during the 12th European Society Medical Oncology (ESMO)/World Congress Gastrointestinal Cancer (WCGIC) in Barcelona many important and controversial topics on the diagnosis and management of patients with gastric cancer.This article summarizes the recommendations and expert opinion on gastric cancer.It discusses and reflects on the regional differences in the incidence and care of gastric cancer, the definition of gastro-esophageal junction and its implication for treatment strategies and presents the latest recommendations in the staging and treatment of primary and metastatic gastric cancer.Recognition is given to the need for larger and well-designed clinical trials to answer many open questions. methodsAt the 2010 Barcelona European Society Medical Oncology/World Congress Gastrointestinal Cancer (ESMO/WCGIC) meeting a panel of invited experts involved in the care of gastric cancer conducted a structured discussion on the different aspects of gastric cancer care.The panel is composed of experts from the different disciplines involved in the care of gastric cancer: gastroenterologists, medical oncologists, radiation oncologists and oncological surgeons.Experts were selected on their scientific merits and their recognition as international opinion leaders.The panel was presented with a detailed questionnaire prior to the meeting.Answers are summarized and then discussed in an extended forum.Conclusions of the recommendations and expert opinion are based on the published data and on clinical experience.The expert opinion recommendations do not therefore represent an official guideline or true consensus statements.The publication aims to guide clinicians in the hands on decisions encountered in the management of gastric cancer.introduction Gastric adenocarcinomas are anatomically divided into true gastric cancer, also referred as gastric, non-cardia cancers, which still comprises the majority of cases, and gastroesophageal junction (GEJ) adenocarcinomas, also referred as proximal gastric or cardia carcinomas.The GEJ cancers and non-GEJ cancers clearly vary in incidence trends, geographical distrubition, proposed etiology, clinical presentation and treatment strategies.Gastric carcinoma is the fourth most common malignancy worldwide [1] and it is the second most common cause of death [2].Incidence varies greatly across the different world regions with a predominance of 26.9 per 100 000 per year (PY) in Asian males as opposed to 7.4 per 100 000 PY in their North American counterparts [1].The decrease in incidence described in the past few decades reflects mainly the decrease in noncardia cancers while the GEJ cancers are stable or even clearly more frequent in some parts of the world [3][4].A recent account of the trends in the USA gathered from the Surveillance, Epidemiology and End Results (SEER) data
Referência(s)